CELL THERAPEUTICS INC Form SC 13G/A February 14, 2003

> UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G Under the Securities Exchange Act of 1934

Amendment No.: 2\*

Name of Issuer: Cell Therapeutics, Inc.

Title of Class of Securities: Common Stock

CUSIP Number: 15093410-7

Date of Event Which Requires Filing of this Statement: 12/31/2002

Check the appropriate box to designate the rule pursuant to which this Schedule if filed.

[X] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ ] Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No.: 15093410-7

- NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Janus Capital Management LLC EIN #75-3019302
- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
   a. \_\_\_\_
   b. \_X\_
- 3. SEC USE ONLY
- 4. CITIZENSHIP OR PLACE OF ORGANIZATION

Colorado

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

- 5. SOLE VOTING POWER 0\*\*
- 6. SHARED VOTING POWER -0-
- 7. SOLE DISPOSITIVE POWER 0\*\*
- 8. SHARED DISPOSITIVE POWER -0-
- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  $_{0}\star\star$
- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  $$\rm N/A$$
- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
   0.0%\*\*
- 12. TYPE OF REPORTING PERSON
  IA, HC
  \*\* See Item 4 of this filing

CUSIP No.: 15093410-7

- NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Janus Global Life Sciences Fund 84-1474315
- CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
   a. \_\_\_\_\_
   b. \_X\_\_
- 3. SEC USE ONLY
- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Massachusetts

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

- 5. SOLE VOTING POWER 0\*\*
- 6. SHARED VOTING POWER -0-
- 7. SOLE DISPOSITIVE POWER
   0\*\*
- 8. SHARED DISPOSITIVE POWER -0-

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0\*\*

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES N/A 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.0%\*\* 12. TYPE OF REPORTING PERSON IV \*\* See Item 4 of this filing Ttem 1. (a). Name of Issuer: Cell Therapeutics, Inc. ("Cell Therapeutics") (b). Address of Issuer's Principal Executive Offices: 501 Elliott Avenue West, Suite 400 Seattle, WA 98119 Item 2. (a).-(c). Name, Principal Business Address, and Citizenship of Persons Filing: Janus Capital Management LLC ("Janus Capital") (1)100 Fillmore Street Denver, Colorado 80206-4923 Citizenship: Colorado Janus Global Life Sciences Fund (2)100 Fillmore Street Denver, Colorado 80206-4923 Citizenship: Massachusetts (d). Title of Class of Securities: Common Stock (e). CUSIP Number: 15093410-7 Item 3. This statement is filed pursuant to Rule 13d-1 (b) or 13d-2(b) and the person filing, Janus Capital, is an investment adviser in accordance with Section 240.13d-1(b)(ii)(E) as well as a parent holding company/control person in accordance with Section 240.13d-1(b)(ii)(G). See Item 4 for additional information. Janus Global Life Sciences Fund is an Investment Company registered under Section 8 of the Investment Company Act of 1940. Item 4. Ownership The information in items 1 and 5 through 11 on the cover page(s)

Janus Capital has an indirect 100% ownership stake in Bay Isle

on Schedule 13G is hereby incorporated by reference.

Financial LLC ("Bay Isle") and an indirect 50.1% ownership stake in Enhanced Investment Technologies LLC ("INTECH"). Due to the above ownership structure, holdings for Janus Capital, Bay Isle and INTECH are aggregated for purposes of this filing. Janus Capital, Bay Isle and INTECH are registered investment advisers, each furnishing investment advice to various investment companies registered under Section 8 of the Investment Company Act of 1940 and to individual and institutional clients (collectively referred to herein as "Managed Portfolios").

Janus Global Life Sciences Fund is an investment company registered under the Investment Company Act of 1940 and is one of the Managed Portfolios to which Janus Capital provides investment advice.

Item 5. Ownership of Five Percent or Less of a Class

This statement is being filed to report the fact that the reporting persons have ceased to be the beneficial owners of more than five percent of the class of securities.

Item 6. Ownership of More than Five Percent on Behalf of Another  $\ensuremath{\mathsf{Person}}$ 

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

Not applicable.

Item 8. Identification and Classification of Members of the Group

Not applicable.

Item 9. Notice of Dissolution of Group

Not applicable.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect.

#### SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

JANUS CAPITAL MANAGEMENT LLC

By /s/ Heidi J. Walter Heidi J. Walter, 02/14/2003 Date

Vice President & Assistant General Counsel

JANUS GLOBAL LIFE SCIENCES FUND

By /s/ Heidi J. Walter 02/14/2003 Heidi J. Walter, Date Vice President & Assistant General Counsel